Payment overview · 2025
General Payments
$366.36
16 reported records · 5 companies
Healthcare provider profile · identity verified
Joanne Galasso
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARLTON, NJ · NPI 1932505211
Verified facts
What the public records show
CMS Open Payments records show Joanne Galasso received $366.36 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $172.07 | 47.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.70 | 22.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.09 | 13.7% | 3 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $34.88 | 9.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.62 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $366.36 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $159.05 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.70 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $13.02 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 34 |
| Lisinopril | Lisinopril | 174 | 29 |
| Metformin Hcl | Metformin Hcl | 163 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 20 |
| Omeprazole | Omeprazole | 155 | 24 |
| Montelukast Sodium | Montelukast Sodium | 120 | 15 |
| Gabapentin | Gabapentin | 103 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | suppressed |
| Losartan Potassium | Losartan Potassium | 80 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 12 |
| Furosemide | Furosemide | 75 | 13 |
| Carvedilol | Carvedilol | 74 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $366.36 · 16 records | GlaxoSmithKline, LLC. | CAPLYTA, FANAPT, Kerecis GraftGuide, Kerecis SurgiClose, NUCALA, TRELEGY ELLIPTA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error